1. Practical Recommendations for COPD:

3. The Burden of COPD

4. The ABCD Assessment Tool

5. GOLD 2017: New Pharmacological Treatment Recommendations

6. Indacaterol/Glycopyrronium vs Monocomponents and Placebo in Patients With COPD

7. SPARK: Indacaterol/Glycopyrronium vs Glycopyrronium and Tiotropium

8. Exacerbation Rates With Salmeterol/Fluticasone Combination and Tiotropium: INSPIRE Study

9. Indacaterol/Glycopyrronium vs Salmeterol-Fluticasone in the ILLUMINATE Study

10. Effect of Indacaterol/Glycopyrronium on FEV1 AUC0−12h at Week 26 in Subgroups

11. TDI Focal Score at Weeks 12 and 26

12. SGRQ Total Score at Week 26

13. Indacaterol/Glycopyrronium vs Salmeterol-Fluticasone Effect on Trough FEV1

14. Indacaterol/Glycopyrronium Significantly Increased Time to First Moderate or Severe COPD Exacerbation vs SFC

15. Reduced Exacerbations With Indacaterol/Glycopyrronium vs SFC in Patients With an Exacerbation in the Previous Year

16. Effect of ICS on Preventing COPD Exacerbations

17. Use of ICS and Risk for Pneumonia: Dose-Response Relationship

18. WISDOM: ICS Withdrawal Did Not Increase the Exacerbations in Patients With Severe COPD

19. GOLD 2017: New Pharmacological Treatment Recommendations (cont)

20. GOLD 2017: Recommendations in Groups C and D

21. Risk Factors for Pneumonia on ICS

22. Reported Pneumonia in Patients With COPD: Findings From the INSPIRE Study

23. Patients Without an Indication for ICS

24. Practical Recommendations for ICS Withdrawal/Reduction

25. GOLD 2017: Treatment Recommendations in Group D

26. Use of ICS and Risk for Pneumonia: Dose-Response Relationship (cont)

27. Available Therapies for COPD

28. Current Concepts in Targeting COPD Pharmacotherapy

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)